Natalizumab Effective for Achieving NEDA-3 in Adolescents With MS
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Journal of the Neurological Sciences
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Effect of natalizumab treatment on the rate of No Evidence of Disease Activity in young adults with multiple sclerosis in relation to pubertal stage
J. Neurol. Sci. 2022 Jan 15;432(xx)120074, S Menascu, A Fattal-Valevski, A Vaknin-Dembinsky, R Milo, K Geva, D Magalashvili, M Dolev, S Flecther, A Kalron, S Miron, C Hoffmann, R Aloni, M Gurevich, A AchironFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.